SCHEMBL1105410

SCHEMBL1105410

Cc1cccc2c1ccn2CCC(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.64
KMT2A Q03164 8/20 0.64
LMNA P02545 1/20 0.59
TSHR P16473 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
PKM P14618 3/20 0.58
ALDH1A1 P00352 6/20 0.55
SCN3A Q9NY46 2/20 0.55
POLB P06746 2/20 0.53
MAPT P10636 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MCL1 Q07820 1/20 0.53
TDP1 Q9NUW8 2/20 0.52
RECQL P46063 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
BLM P54132 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9972232 0.92 MEN1 (0.62) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL1102269 0.90 LMNA (0.59) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL1102130 0.90 PKM (0.59) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL1102268 0.89 PKM (0.61) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL1102121 0.86 PKM (0.64) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL1102126 0.83 ALDH1A1 (0.60) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL9974118 0.81 SCN3A (0.60) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL9972236 0.81 PKM (0.61) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL9972245 0.81 MAPT (0.60) MEN1KMT2ALMNATSHRSMN1; SMN2
SCHEMBL9972241 0.81 MEN1 (0.59) MEN1KMT2ALMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 MEN1 2329/4885KMT2A 3111/4885LMNA 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.